Project Code
Target
Indicant
MOA & Molecule Type
Phase 3
Phase 2
Phase 1
Preclinical
Peptide Receptor
Radionuclide Therapy
Renal cancer
CAIX
CBT-001
Late
Discovery
Peptide Receptor
Radionuclide
Therapy(Pro-Drug)
Neuroendocrine tumor
SSTR2
PRRT, PDC, Pro-drug
solid cancer
FAP-α
CBT-004
CNP
Achondrogenesis
NPR-B
CBT-005
Pipeline
Early
Discovery
Target: FAP-α
Indicant: solid cancer
MOA & Molecule Type: PRRT, PDC, Pro-drug
Development stage: R&D
Summary: FAP-α is a protein that is expressed on the surface of cancer-related fibroblasts and is overexpressed in most solid cancer tissues as cancer cells grow.
Based on the CUSTM platform, we have a low-molecular D-peptide candidate that can effectively target FAP-α, and show experimental results that more effectively inhibit FAP-α due to its superior stability and selectivity compared to other Quinnoline-based low-molecular compounds in clinical trials.
CBT-004